CytoDyn to Attend AACR Special Conference on Cancer Immunity Mechanisms

CytoDyn Inc., a company specializing in oncology treatments, is set to present at the AACR Special Conference on Mechanisms of Cancer Immunity and Cancer-related Autoimmunity in Montreal, Canada. The main focus of the presentation will be on the effects of leronlimab, a groundbreaking monoclonal antibody targeting the CCR5 receptor, on metastatic triple-negative breast cancer (TNBC).

Dr. Richard Pestell, a Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will be giving a podium presentation on the potential of leronlimab to transform ‘cold’ tumors into ‘hot’ ones. This transformation could significantly enhance the responsiveness of these tumors to checkpoint inhibitors, especially in aggressive diseases like metastatic TNBC, which currently face significant treatment challenges. The research findings also aim to provide insights into the underlying mechanism of action of leronlimab, which could have broader applications in solid tumors with limited treatment options.

The abstract of the presentation highlights the association between CCR5 inhibition using leronlimab and enhanced PD-L1 expression, ICI response, and improved long-term survival in metastatic TNBC. Dr. Pestell’s poster presentation is scheduled for September 26, 2025, from 6:30 p.m. to 8:30 p.m. EDT, while his oral presentation will take place on September 27, 2025, from 10:25 a.m. to 10:40 a.m. EDT.

CytoDyn is a biotechnology company dedicated to advancing leronlimab, a monoclonal antibody that targets the CCR5 receptor. This receptor plays a crucial role in immune function and is implicated in various conditions, including cancer, infectious diseases, and autoimmune disorders. The mission of CytoDyn is to enhance the quality of life for patients through innovative therapies, emphasizing integrity, responsibility, and service as they strive to bring transformative treatments to patients globally.

The Company has issued a cautionary note regarding forward-looking statements made in this news release. These statements are based on current expectations and assumptions about future events, and readers are advised to exercise caution. The risks, uncertainties, and other factors that may cause actual results to differ from these statements are outlined in the Company’s reports filed with the Securities and Exchange Commission. CytoDyn Inc. pledges to update any forward-looking statements as required by law, with a commitment to transparency and compliance.

In conclusion, the upcoming presentation by CytoDyn at the AACR Special Conference represents a significant step in advancing leronlimab’s potential as a therapeutic option for challenging conditions like metastatic TNBC. The research findings have the potential to revolutionize treatment strategies for solid tumors with limited therapeutic avenues, offering new hope to patients worldwide.